Neurogene Inc.
NASDAQ:NGNEBiotechnology
Healthcare
$23.14 +2.47%
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
52W Low $14.65High $37.27
Volume 0.25M
Average 0.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$77.17M
FY 2025 · Annual
Investing Cash Flow
$14.00M
FY 2025 · Annual
Financing Cash Flow
$30.43M
FY 2025 · Annual
-83.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Depreciation & Amortization | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| Deferred Income Tax | 0 | 0 | (105K) | 0 | 0 |
| Stock-Based Compensation | 896K | 1.25M | 1.42M | 8.32M | 14.18M |
| Change in Working Capital | 1.6M | (2.7M) | (4.02M) | (5.96M) | 268K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.98M | (3.61M) | 667K | (77K) | 627K |
| Other Working Capital | (1.39M) | 912K | (4.69M) | (5.88M) | (359K) |
| Other Non-Cash Items | 679K | 608K | (15.69M) | (1.07M) | (4.37M) |
| Operating Cash Flow | (46.4M) | (52.82M) | (51.42M) | (70.6M) | (77.17M) |
| Capital Expenditures | (18.37M) | (2.23M) | (321K) | (808K) | (1.18M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (198.45M) | (269.51M) |
| Sales of Investments | 0 | 0 | 5M | 74M | 284.7M |
| Other Investing Activities | 0 | 0 | 20.96M | 0 | 0 |
| Investing Cash Flow | (18.37M) | (2.23M) | 25.64M | (125.26M) | 14M |
| Debt Repayment | 0 | (1K) | (29K) | (52K) | (61K) |
| Common Stock Issued | 287K | 73K | 92.34M | 189.59M | 30.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 168K | (5.47M) | 0 |
| Financing Cash Flow | 51.06M | 66.53M | 92.48M | 184.07M | 30.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.71M) | 11.48M | 66.7M | (11.79M) | (32.74M) |
| Free Cash Flow | (64.77M) | (55.05M) | (51.74M) | (71.41M) | (78.36M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$90.4M
+ D&A$3.1M
+ Stock-Based Comp$14.2M
+ Deferred Tax$0
+ Working Capital$268.0K
- Other Non-Cash-$4.4M
= Operating Cash Flow-$77.2M
- Capex-$1.2M
= Free Cash Flow-$78.4M
Analysis
FY2025 free cash flow is -$78.4M. FCF conversion is 86.7% of net income. Operating cash flow was -$77.2M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $14.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
Does NGNE generate free cash flow?
Neurogene Inc. (NGNE) generated -$78.36M of free cash flow in fiscal 2025.
How much operating cash flow does NGNE produce?
Operating cash flow was -$77.17M, before capital expenditures of $1.18M.
Continue the stock analysis
Jump to another research area for this company.